Drug Profile
Research programme: chemokine receptor type 4 inhibitors: Pierre Fabre
Alternative Names: Anti-CXCR4 antibodies - Pierre Fabre Centre d’Immunologie; Project F50067 - Pierre Fabre Centre d’ImmunologieLatest Information Update: 19 Sep 2023
Price :
$50
*
At a glance
- Originator Pierre Fabre Centre d'Immunologie
- Class Monoclonal antibodies
- Mechanism of Action CCR4 receptor antagonists; Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 19 Sep 2023 Discontinued - Preclinical for Cancer in France (Parenteral) (Pierre Fabre Centre d'Immunologie website, September 2023)
- 28 Sep 2020 No recent reports of development identified for preclinical development in Cancer in France (Parenteral)
- 30 Aug 2016 Preclinical trials in Cancer in France (Parenteral) before August 2016 (Pierre Fabre Centre d’Immunologie pipeline, August 2016)